木薯資源(00841.HK)聯合一酒精生產商共同競投贛榆酒精廠
格隆匯12月9日丨木薯資源(00841.HK)公告,於2019年11月28日,公司子公司日照雨順木薯有限公司(日照雨順)與中國國內一間酒精生產商訂立一份聯合體協議書,根據該份聯合體協議書,日照雨順與酒精生產商同意共同競投一間位於中國江蘇省贛榆的酒精廠(贛榆酒精廠);及倘若勝出擬共同競投,日照雨順與酒精生產商將成立合資公司擁有及經營贛榆酒精廠。
現時贛榆酒精廠的擁有者及潛在賣家(潛在賣)正在進行破產清算,而贛榆酒精廠為其中一項待處置資產。因此,擬共同競投必須得到潛在賣家的破產管理人及債權人委員會批准同意。雖然潛在賣家的破產管理人初步同意擬共同競投,惟仍需待潛在賣家的債權人委員會批准同意。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.